antibody

Anti-Human Platelet Factor 4, Purified (Clone: RTO) (Mouse IgG2b)

MBS520501

0.2 mg

385 USD

monoclonal

mouse

nonconjugated

RTO

western blot, ELISA, enzyme immunoassay

Antibody

Anti-Human Platelet Factor 4, Purified (Clone: RTO) (Mouse IgG2b)

Platelet Factor 4

Platelet Factor 4, Purified (Clone: RTO) (Mouse IgG2b); Anti-Human Platelet Factor IV

platelet factor 4; Platelet factor 4 variant; platelet factor 4 variant; PF4alt; PF4var1; C-X-C motif chemokine 4; platelet factor 4, variant 1 (PF4-like); platelet factor 4 variant 1; C-X-C motif chemokine 4 variant; CXCL4L1; PF4alt; PF4var1

PF4V1; PF4V1; PF4A; CXCL4L1; CXCL4V1; PF4-ALT; SCYB4V1; CXCL4V1; SCYB4V1

PF4V_HUMAN

Monoclonal

Mouse IgG2bkappa

RTO

Mouse

Human

104

Platelet Factor 4 (This antibody is specific for Human Platelet Factor IV.)

Purified

1.0 mg/ml

Store at +4 degree C. For long term storage, aliquot and freeze unused portion at -20 degree C in volumes appropriate for single use. Avoid freeze thaw cycles

ELISA (EIA), Western Blot (WB)

This antibody is suitable for use in ELISA. ELISA: Use at a concentration of 0.016ug/ml

Immunogen: Human Factor IV purified from the supernatant of thrombin activated platelets.

Presentation: Purified IgG buffered in PBS and 0.02% NaN3. (Purified from ascitic fluid via Protein G Chromatography)

Platelet factor IV is a 70 aa protein released from the alpha granules of activated platelets. PF4 is synthesized by bone marrow megakaryocytes and stored in alpha granules as a non-covalent bound tetramer. Platelet factor IV binds with high affinity to heparin and plays a role in inflammation and wound repair. PF4 is a chemoattractant for neutrophils, monocytes and fibroblasts and has been reported to be an immunologic regulator that inhibits suppressor T-cell activity. (clone RTO) is seen to bind free PF4 in the absence of any bound heparin. This is unlike (clone KKO), which binds PF4/heparin complexes to a similar degree as auto-antibodies found in individuals with Heparin-Induced Thrombocytopenia/Thrombosis (HIT/HITT).

292390

AAA60067.1

P10720

11,553 Da

Cell Surface Interactions At The Vascular Wall Pathway (106062); Chemokine Signaling Pathway (99051); Chemokine Signaling Pathway (96864); Common Pathway (106060); Cytokine-cytokine Receptor Interaction Pathway (83051); Cytokine-cytokine Receptor Interaction Pathway (460); Formation Of Fibrin Clot (Clotting Cascade) Pathway (106057); Hemostasis Pathway (106028)

Function: Inhibitor of angiogenesis. Inhibitor of endothelial cell chemotaxis (in vitro). Ref.5. Subunit structure: Homotetramer. Ref.6. Subcellular location: Secreted. Post-translational modification: The N-terminal processed forms of platelet factor 4 variant seems to be produced by proteolytic cleavage. The most abundant form is Platelet factor 4 variant(5-74). Miscellaneous: Binding to heparin is much weaker than in the close homolog PF4/CXCL4. Sequence similarities: Belongs to the intercrine alpha (chemokine CxC) family. Mass spectrometry: Molecular mass is 8250.9 Da from positions 31 - 104. Determined by ESI. Platelet factor 4 variant. Ref.5Molecular mass is 7877.7 Da from positions 34 - 104. Determined by ESI. Platelet factor 4 variant(4-74). Ref.5Molecular mass is 7805.8 Da from positions 35 - 104. Determined by ESI. Platelet factor 4 variant(5-74). Ref.5Molecular mass is 7678.6 Da from positions 36 - 104. Determined by ESI. Platelet factor 4 variant(6-74). Ref.5

0.2 mg

385 USD